Literature DB >> 11687197

Antidepressants versus psychological treatments and their combination for bulimia nervosa.

J Bacaltchuk1, P Hay, R Trefiglio.   

Abstract

BACKGROUND: Psychotherapeutic approaches, mainly cognitive behavior therapy, and antidepressant medication are the two treatment modalities that have received most support in controlled outcome studies of bulimia nervosa.
OBJECTIVES: The primary objective was to conduct a systematic review of all RCTs comparing antidepressants with psychological approaches or comparing their combination with each single approach for the treatment of bulimia nervosa. SEARCH STRATEGY: (1) electronic searches of MEDLINE (1966 to December 2000), EMBASE (1980-December 2000), PsycLIT (to December 2000), LILACS & SCISEARCH (to 1999) (2) the Cochrane Register of Controlled Trials and the Cochrane Depression, Anxiety and Neurosis Group Register - ongoing (3) handsearches of the references of all identified trials (4) contact with the pharmaceutical companies and the principal investigator of each included trial (5) handsearch of the International Journal of Eating Disorders - ongoing INCLUSION CRITERIA: every randomized controlled trial in which antidepressants were compared with psychological treatments or the combination of antidepressants with psychological approaches was compared to each treatment alone, to reduce the symptoms of bulimia nervosa in patients of any age or gender. Quality criteria: reports were considered adequate if they were classified as A or B according to the Cochrane Manual. DATA COLLECTION AND ANALYSIS: Data were extracted independently by two reviewers for each included trial. The main outcome for efficacy was full remission of bulimic symptoms, defined as 100% reduction in binge or purge episodes from baseline to endpoint. Dichotomous data was evaluated by the relative risks and 95% confidence intervals around this measure, based on the random effects model; continuous data was evaluated by the average difference and the 95% confidence interval. Number needed to treat (NNT) and number needed to harm (NNH) were calculated using the inverse of the absolute risk reduction. MAIN
RESULTS: Five trials were included in comparison one (antidepressants versus psychological treatments), five in comparison two (antidepressants versus the combination) and seven in comparison three (psychological treatments versus the combination). Remission rates were 20% for single antidepressants compared to 39% for single psychotherapy (DerSimonian-Laird Relative Risk = 1.28; 95% Confidence Interval = 0.98;1.67). Dropout rates were higher for antidepressants than for psychotherapy (DerSimonian-Laird Relative Risk = 2.18; 95% Confidence Interval = 1.09;4.35). The NNH for a mean treatment duration of 17.5 weeks was 4 (95% confidence interval = 3;11). Comparison two found remission rates of 42% for the combination versus 23% for antidepressants (DerSimonian-Laird Relative Risk = 1.38; 95% Confidence Interval = 0.98;1.93). Comparison three showed a 36% pooled remission rate for psychological approaches compared to 49% for the combination (DerSimonian-Laird Relative Risk = 1.21; 95% Confidence Interval = 1.02;1.45). The NNT for a mean treatment duration of 15 weeks was 8 (95% Confidence Interval = 4;320). Dropout rates were higher for the combination compared to single psychological treatments (DerSimonian-Laird Relative Risk = 0.57; 95% Confidence Interval = 0.38;0.88). The NNH was 7 (95% Confidence Interval = 4;21). REVIEWER'S
CONCLUSIONS: Using a more conservative statistical approach, combination treatments were superior to single psychotherapy. This was the only statistically significant difference between treatments. The number of trials might be insufficient to show the statistical significance of a 19% absolute risk reduction in efficacy favouring psychotherapy or combination treatments over single antidepressants. Psychotherapy appeared to be more acceptable to subjects. When antidepressants were combined to psychological treatments, acceptability of the latter was significantly reduced.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11687197      PMCID: PMC6999807          DOI: 10.1002/14651858.CD003385

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  48 in total

1.  Antidepressants versus placebo for the treatment of bulimia nervosa: a systematic review.

Authors:  J Bacaltchuk; P Hay; J J Mari
Journal:  Aust N Z J Psychiatry       Date:  2000-04       Impact factor: 5.744

2.  Antidepressants versus psychotherapy for bulimia nervosa: a systematic review.

Authors:  J Bacaltchuk; R P Trefiglio; I R de Oliveira; M S Lima; J J Mari
Journal:  J Clin Pharm Ther       Date:  1999-02       Impact factor: 2.512

3.  Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology.

Authors:  M M Fichter; R Krüger; W Rief; R Holland; J Döhne
Journal:  J Clin Psychopharmacol       Date:  1996-02       Impact factor: 3.153

4.  Maintenance treatment and 6-month outcome for bulimic patients who respond to initial treatment.

Authors:  R L Pyle; J E Mitchell; E D Eckert; D Hatsukami; C Pomeroy; R Zimmerman
Journal:  Am J Psychiatry       Date:  1990-07       Impact factor: 18.112

5.  A comparison study of antidepressants and structured intensive group psychotherapy in the treatment of bulimia nervosa.

Authors:  J E Mitchell; R L Pyle; E D Eckert; D Hatsukami; C Pomeroy; R Zimmerman
Journal:  Arch Gen Psychiatry       Date:  1990-02

6.  Medication and psychotherapy in the treatment of bulimia nervosa.

Authors:  B T Walsh; G T Wilson; K L Loeb; M J Devlin; K M Pike; S P Roose; J Fleiss; C Waternaux
Journal:  Am J Psychiatry       Date:  1997-04       Impact factor: 18.112

Review 7.  [Pharmacologic treatment of bulimia].

Authors:  M Corcos; M Flament; F Atger; P Jeammet
Journal:  Encephale       Date:  1996 Mar-Apr       Impact factor: 1.291

Review 8.  Psychotherapy for bulimia nervosa and binging.

Authors:  P J Hay; J Bacaltchuk
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 9.  Comorbidity and medical complications of bulimia nervosa.

Authors:  J E Mitchell; S M Specker; M de Zwaan
Journal:  J Clin Psychiatry       Date:  1991-10       Impact factor: 4.384

10.  Treating bulimia with desipramine. A double-blind, placebo-controlled study.

Authors:  P L Hughes; L A Wells; C J Cunningham; D M Ilstrup
Journal:  Arch Gen Psychiatry       Date:  1986-02
View more
  18 in total

Review 1.  Anorexia nervosa.

Authors:  Jane Morris; Sara Twaddle
Journal:  BMJ       Date:  2007-04-28

Review 2.  Using technology within the treatment of eating disorders: a clinical practice review.

Authors:  Rebecca M Shingleton; Lauren K Richards; Heather Thompson-Brenner
Journal:  Psychotherapy (Chic)       Date:  2013-03-25

3.  Binge eating disorder in obesity: comparison of different therapeutic strategies.

Authors:  E Molinari; M Baruffi; M Croci; S Marchi; M L Petroni
Journal:  Eat Weight Disord       Date:  2005-09       Impact factor: 4.652

Review 4.  Bulimia nervosa.

Authors:  Phillipa J Hay; Angélica Medeiros Claudino
Journal:  BMJ Clin Evid       Date:  2010-07-19

Review 5.  Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa.

Authors:  Susan L McElroy; Anna I Guerdjikova; Nicole Mori; Francisco Romo-Nava
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

6.  Predictors of dropout in face-to-face and internet-based cognitive-behavioral therapy for bulimia nervosa in a randomized controlled trial.

Authors:  Hunna J Watson; Michele D Levine; Stephanie C Zerwas; Robert M Hamer; Ross D Crosby; Caroline S Sprecher; Amy O'Brien; Benjamin Zimmer; Sara M Hofmeier; Hans Kordy; Markus Moessner; Christine M Peat; Cristin D Runfola; Marsha D Marcus; Cynthia M Bulik
Journal:  Int J Eat Disord       Date:  2016-11-12       Impact factor: 4.861

7.  Drop-out rate in eating disorders: could it be a function of patient-therapist relationship?

Authors:  M Morlino; G Di Pietro; R Tuccillo; A Galietta; M Bolzan; I Senatore; M Marozzi; L Valoroso
Journal:  Eat Weight Disord       Date:  2007-09       Impact factor: 4.652

Review 8.  [Eating disorders: state of the art research and future challenges].

Authors:  U Voderholzer; U Cuntz; S Schlegl
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

Review 9.  What can we learn from consumer studies and qualitative research in the treatment of eating disorders?

Authors:  L Bell
Journal:  Eat Weight Disord       Date:  2003-09       Impact factor: 4.652

10.  Mental health first aid for eating disorders: pilot evaluation of a training program for the public.

Authors:  Laura M Hart; Anthony F Jorm; Susan J Paxton
Journal:  BMC Psychiatry       Date:  2012-08-02       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.